TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07328948 will be administered as oral suspensions every QD over 14 days
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07328948 will be administered as oral suspensions QD over 14 days
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
Study: NCT06134037
Drug: Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
Study: NCT05487950
Drug: Rivaroxaban group
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
Study: NCT00002019
Drug: Amphotericin B, Lipid-based
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002019
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05293119
Drug: JAK-2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this trial, one group will receive the tofacitinib 5 mg twice daily
Study: NCT05464979
Drug: Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]
Normalized name: ESKETAMINE HYDROCHLORIDE 28 mg in 0.2 mL NASAL SOLUTION [Spravato]
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.
Study: NCT04747470
Drug: GS-3583
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an intravenous (IV) infusion
Study: NCT04747470
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV infusion
Study: NCT04747470
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an IV infusion
Study: NCT04747470
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an IV infusion
Study: NCT04747470
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an IV infusion
Study: NCT04747470
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an IV infusion
Study: NCT05241340
Drug: Sasanlimab
Normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
Study: NCT06399835
Drug: Enavogliflozin
Normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enavogliflozin 0.3mg once daily
Study: NCT06399835
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 15mg once daily
Study: NCT05638126
Drug: HRS-1780 table or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HRS-1780 table or placebo single dose
Study: NCT05638126
Drug: HRS-1780 table or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HRS-1780 table or placebo single dose with food effect
Study: NCT05638126
Drug: HRS-1780 table or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HRS-1780 table or placebo multiple dose
Study: NCT04728802
Drug: Proxalutamide
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide 300mg q.d
Study: NCT05782777
Drug: ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
Study: NCT05877872
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Study: NCT05969899
Drug: FOLFIRI+Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
Study: NCT00849238
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04656600
Drug: Cerezyme® / Imiglucerase
DrugBank: Imiglucerase (DB00053)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
Study: NCT00002156
Drug: Fomivirsen sodium
Normalized name: Fomivirsen Sodium
DrugBank: Fomivirsen (DB06759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002156
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04910594
Drug: recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
Study: NCT05387187
Drug: Pu Yang Wan Wu Tang plus Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
Study: NCT05387187
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 100mg TID
Study: NCT05582798
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride 09.% intravenous infusion
Study: NCT04967573
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 20 mg or 10 mg for 3 months
Study: NCT00115414
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00115414
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06239727
Drug: PD-1 blocking antibody
Normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.
Study: NCT06239727
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Study: NCT06239727
Drug: Cisplatin (80 mg/m2)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study: NCT06239727
Drug: Cisplatin (100 mg/m2)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study: NCT05192239
Drug: THC 5
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 milligrams of THC in gummy form
Study: NCT00054795
Drug: Motexafin Gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05163483
Drug: Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years
Study: NCT05460338
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: native form of Vitamin D.
Study: NCT05344495
Drug: midazolam group
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
Study: NCT00000814
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000814
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000814
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000929
Drug: Nonoxynol-9
Normalized name: Nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04908592
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
Study: NCT05839314
Drug: Renin-angiotensin-aldosterone system inhibitors (RASI)
DrugBank: Aldosterone (DB04630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening.
Study: NCT04898699
Drug: Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
Study: NCT03717181
Drug: Lixivaptan
Normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of lixivaptan optimized using a predetermined titration protocol.
Study: NCT06025071
Drug: colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
Study: NCT05580250
Drug: Iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously (IV).
Study: NCT05580250
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally.
Study: NCT05056116
Drug: Surufatinib Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
Study: NCT06067841
Drug: BMS-986460
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days.
Study: NCT05314231
Drug: ALXN1720
Normalized name: IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
DrugBank: Gefurulimab (DB18928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
Study: NCT04757974
Drug: Fostemsavir 600 mg
Normalized name: fostemsavir 600 MG
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir tablets will be administered via oral route.
Study: NCT04757974
Drug: Fostemsavir 200 mg
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir tablets will be administered via oral route.
Study: NCT05215951
Drug: osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
Study: NCT05422001
Drug: low dose ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml
Study: NCT06044142
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin and low laser therapy will be used on patients undergoing chemotherapy
Study: NCT04782076
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04782076
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05765500
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
Study: NCT05765500
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
Study: NCT05416840
Drug: Clonidine controlled-release patch
Normalized name: clonidine Extended Release Suspension
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).
Study: NCT05416840
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).
Study: NCT06178627
Drug: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different amphotericin B dosage
Study: NCT06178627
Drug: Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different amphotericin B dosage
Study: NCT03527069
Drug: Crestor 10 mg
Normalized name: Crestor 10 MG Oral Tablet
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, once a day.
Study: NCT05717569
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
Study: NCT05615727
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mcg/kg of undiluted dexmedetomidine \[= 0.02 ml/kg\] and oral placebo tablet
Study: NCT05615727
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zolpidem 10 mg and intranasal saline 0.02 ml/kg
Study: NCT05373108
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
Study: NCT06265454
Drug: low dose atropine eye drops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
Study: NCT04053621
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
Study: NCT05828381
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg,sc,d1,q3w; for a total of 2 cycles.
Study: NCT05828381
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
Study: NCT05828381
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
Study: NCT06020911
Drug: Theracal light cured
Normalized name: kaolin light
DrugBank: Kaolin (DB01575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 primary second molars of 17 children will be capped with Theracal light cured
Study: NCT05059873
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 40mg/day for five consecutive days
Study: NCT05966584
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab 30mg subcutaneously on day -1.
Study: NCT04009759
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
Study: NCT04009759
Drug: Ketamine Injectable Solution
Normalized name: ketamine Injectable Solution
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
Study: NCT05383612
Drug: 3% Diquafosol Sodium Eye Drops
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
Study: NCT04460872
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive testosterone (100 mg/week) by intramuscular injection